ALP Bio raises $2.2M
ALP Bio announced a Pre-Seed round of $2.2M on 29 April 2026. The company operates in HealthTech and is based in Switzerland. It was founded by Christian Vahlensieck, CEO & Co-founder.
Founder
Christian Vahlensieck
CEO & Co-founder, ALP Bio
Outreach angles
- -Christian holds a PhD from University of Zurich and turned his immunology research into the foundation for ALP Bio's organoid platform.
- -He brought on three co-founders including CSO Lucas Schaus, building a wet-lab plus generative AI team focused on antibody drug development risk.
- -The €1.9M pre-seed led by 42CAP with Venture Kick funds development of immune organoid readouts feeding ML models for ADA risk prediction.
Signals
Pre-SeedHealthcareDeep TechAI-NativeRegulated IndustryB2B
Round details
Company: ALP Bio
Domain: alp.bio
Amount: $2.2M
Stage: Pre-Seed
Industry: HealthTech
Country: Switzerland
Announced: 29 April 2026
Other HealthTech raises
Recently funded in Switzerland